Phase II study of capecitabine, irinotecan, and celecoxib in advanced colorectal cancer.

被引：0
|
作者：
El-Rayes, BF
Shields, AF
Vaishampayan, U
Heilbrun, L
Bekaii-Saab, T
Zalupski, MM
Philip, PA
机构：
[1] Karmanos Canc Inst, Detroit, MI USA
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3766
引用
收藏
页码：310S / 310S
页数：1
相关论文
共 50 条
  • [21] Capecitabine in combination with oxaliplatin or with irinotecan in elderly patients with advanced colorectal cancer: Preliminary results of a randomized phase II study
    Rosati, G.
    Cordio, S.
    Bordonaro, R.
    Gebbia, V
    Rinaldi, A.
    Giannitto, G.
    Borsellino, N.
    Reggiardo, G.
    Manzione, L.
    ANNALS OF ONCOLOGY, 2007, 18 : 189 - 189
  • [22] Capecitabine in combination with oxaliplatin or with irinotecan in elderly patients with advanced colorectal cancer: Preliminary results of a randomized phase II study
    Rosati, G.
    Cordio, S.
    Bordonaro, R.
    Gebbia, V
    Rinalci, A.
    Giannitto, G.
    Borsellino, N.
    Reggiardo, G.
    ANNALS OF ONCOLOGY, 2007, 18 : VII28 - VII29
  • [23] Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer
    J H Baek
    J G Kim
    S B Jeon
    Y S Chae
    D H Kim
    S K Sohn
    K B Lee
    Y J Choi
    H J Shin
    J S Chung
    G J Cho
    H Y Jung
    W Yu
    British Journal of Cancer, 2006, 94 : 1407 - 1411
  • [24] Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer
    Baek, J. H.
    Kim, J. G.
    Jeon, S. B.
    Chae, Y. S.
    Kim, D. H.
    Sohn, S. K.
    Lee, K. B.
    Choi, Y. J.
    Shin, H. J.
    Chung, J. S.
    Cho, G. J.
    Jung, H. Y.
    Yu, W.
    BRITISH JOURNAL OF CANCER, 2006, 94 (10) : 1407 - 1411
  • [25] A Phase I Study of Capecitabine, Irinotecan, Celecoxib, and Radiation as Neoadjuvant Therapy of Patients With Locally Advanced Rectal Cancer
    Malik, Imtiaz
    Hussein, Farabi
    Bush, David
    Alqaisi, Munther
    Bernal, Pedro
    Byrd, Janet
    Garberoglio, Carlos
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (03): : 242 - 245
  • [26] A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.
    Boland, Patrick McKay
    Fakih, Marwan
    Attwood, Kristopher
    Robins, Melissa
    Iyer, Renuka V.
    Ma, Wen Wee
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [27] A Phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.
    Cartwright, TH
    Lopez, T
    Vukelja, SJ
    Encarnacion, C
    Boehm, KA
    Asmar, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 284S - 284S
  • [28] A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.
    Boland, Patrick McKay
    Fakih, Marwan
    Lim, Dean
    Attwood, Kristopher
    Tan, Wei
    Mastri, Michalis
    Bies, Robert
    Fountzilas, Christos
    Iyer, Renuka V.
    Ma, Wen Wee
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer.
    Fernando, N
    Yu, D
    Morse, M
    Blobe, G
    Odogwu, L
    Crews, J
    Polito, A
    Honeycutt, W
    Franklin, A
    Hurwitz, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 260S - 260S
  • [30] A phase II study of irinotecan, fluoroxuridine and leucovorin (IFLUX) as a first-line chemotherapy in advanced colorectal cancer.
    Ardalan, B
    Livingstone, A
    Franceschi, D
    Santos, E
    Lima, M
    Kozyreva, O
    Tsai, KT
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 270S - 270S
12345